Vascular diseases represent a major global health burden, encompassing conditions such as atherosclerosis, peripheral artery disease, deep vein thrombosis, and diabetic vascular complications. Current diagnostic modalities, including computed tomography angiography, magnetic resonance angiography, and color Doppler ultrasound, each have inherent constraints related to radiation exposure, contrast agent toxicity, limited functional information, or inadequate spatial resolution. Photoacoustic imaging has emerged as a compelling alternative and complement, combining optical contrast with ultrasonic detection to deliver high-resolution anatomical and functional vascular data without ionizing radiation.

Over the past several years, research groups and clinical investigators have made substantial progress in advancing photoacoustic imaging technology for vascular applications. These improvements span hardware innovation, signal processing algorithms, contrast agent development, and multimodality integration. This article provides a comprehensive technical overview of recent developments in photoacoustic imaging for vascular disease diagnosis and monitoring, with an emphasis on clinically translatable advances and remaining challenges.

Fundamentals of Photoacoustic Imaging

Photoacoustic imaging exploits the photoacoustic effect, in which pulsed laser light absorbed by tissue generates transient heating and subsequent thermoelastic expansion, producing broadband ultrasonic waves. These waves propagate through tissue and are detected by ultrasound transducers at the tissue surface. Reconstruction algorithms similar to those used in conventional ultrasound beamforming then generate images representing the spatial distribution of optical absorption within the tissue.

The key advantage of photoacoustic imaging arises from its hybrid contrast mechanism. While ultrasound imaging reveals acoustic impedance mismatches and optical imaging relies on photon scattering and absorption, photoacoustic signals are directly proportional to the local optical absorption coefficient. Endogenous chromophores such as hemoglobin, melanin, and lipids serve as natural contrast agents, enabling label-free visualization of blood vessels and tissue oxygenation. This combination provides both high optical contrast and the spatial resolution of ultrasound at depths of several centimeters, which is not achievable with purely optical techniques such as confocal microscopy or optical coherence tomography.

In the context of vascular imaging, oxyhemoglobin and deoxyhemoglobin in red blood cells are the dominant absorbing species at visible and near-infrared wavelengths. By acquiring images at multiple wavelengths and applying spectral unmixing algorithms, photoacoustic imaging can map oxygen saturation with high spatial precision. This functional capability is a distinguishing feature that extends beyond what anatomical imaging techniques can provide.

Key Technological Breakthroughs

Recent progress in photoacoustic imaging has been driven by advances in laser technology, detector design, signal processing, and contrast agent development. These improvements have collectively enhanced image quality, depth penetration, acquisition speed, and the range of measurable physiological parameters.

High-Energy Tunable Laser Sources

The quality of photoacoustic images is fundamentally limited by the available laser pulse energy, repetition rate, and wavelength tunability. Solid-state laser systems based on optical parametric oscillators have become more compact and reliable, offering pulse energies in the millijoule range at repetition rates exceeding 100 Hz. These systems enable deep-tissue imaging at depths up to 5 to 7 centimeters in biological tissues. More recently, fiber-coupled laser sources have been developed that deliver light through flexible delivery fibers, facilitating endoscopic or catheter-based photoacoustic imaging for intravascular applications. These fiber-based systems are smaller, more robust, and better suited for clinical integration than traditional free-space laser systems.

Ultra-Wideband Ultrasound Detectors

Ultrasound transducer technology has advanced significantly to meet the specific requirements of photoacoustic imaging. Photoacoustic signals span a wider frequency range than conventional ultrasound echoes, typically from fractions of a megahertz to several tens of megahertz, depending on target size and depth. Broadband polyvinylidene fluoride film transducers and capacitive micromachined ultrasonic transducer arrays now provide the necessary bandwidth for high-fidelity photoacoustic signal detection. These detectors achieve noise-equivalent pressures in the high pascal range, allowing visualization of microvessels with diameters as small as 100 micrometers. Multi-element linear and phased arrays enable real-time imaging at frame rates exceeding 20 frames per second, sufficient for dynamic vascular studies including contrast bolus tracking and perfusion analysis.

Multispectral and Hyperspectral Acquisition

Functional photoacoustic imaging relies on acquiring images at multiple optical wavelengths and decomposing the resulting multispectral data into chromophore concentration maps. Recent algorithmic developments, including model-based inversion using the Monte Carlo method for light transport simulation and machine learning-based spectral unmixing, have improved the accuracy and computational efficiency of oxygen saturation estimation. Hyperspectral systems capable of acquiring images at dozens of wavelength points within a few seconds are now entering preclinical use, offering detailed spectral signatures that can distinguish not only oxyhemoglobin and deoxyhemoglobin but also lipids, water, and exogenous contrast agents such as indocyanine green. These advances enable quantitative measurements of oxygen extraction fraction, blood flow, and metabolic rate of oxygen consumption in vascular territories.

Contrast Agent Innovation

Exogenous contrast agents extend the capabilities of photoacoustic imaging beyond endogenous chromophores. Gold nanoparticles, carbon nanotubes, and synthetic organic dyes have been developed as molecularly targeted photoacoustic contrast agents. For vascular applications, agents targeting endothelial cell surface markers such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 allow visualization of inflamed, atherosclerotic-prone endothelium. Photoacoustic imaging with targeted nanoparticles has been demonstrated in murine models of atherosclerosis, showing selective accumulation in plaque regions with high macrophage infiltration. Additionally, photoacoustic-ultrasound dual-modality contrast agents using perfluorocarbon nanodroplets or microbubbles combined with absorbing dyes enable combined contrast-enhanced ultrasound and photoacoustic imaging from a single injection, providing complementary information about vascular structure and function.

Clinical Applications in Vascular Disease

The technological advances described above have translated into a growing body of preclinical and early clinical evidence supporting photoacoustic imaging for specific vascular disease applications. While large-scale clinical trials are still limited, the potential clinical utility is becoming increasingly clear.

Atherosclerosis and Plaque Characterization

Atherosclerotic plaque rupture is the leading cause of myocardial infarction and stroke. Current imaging techniques can identify luminal stenosis but provide limited information about plaque composition and vulnerability. Photoacoustic imaging offers the ability to detect lipid-rich necrotic cores and intraplaque hemorrhage, both hallmarks of high-risk plaques. At near-infrared wavelengths around 1200 nanometers, lipids exhibit strong absorption that can be spectrally distinguished from water and hemoglobin. Intravascular photoacoustic imaging catheters using fiber-optic light delivery and miniaturized ultrasound transducers have been developed for coronary artery imaging. These catheters achieve resolution of approximately 100 micrometers at depths of several millimeters, sufficient to resolve the layered structure of human atherosclerotic plaques. Studies in ex vivo coronary specimens have demonstrated excellent correlation between photoacoustic lipid maps and histology, suggesting clinical potential for identifying vulnerable plaques before they rupture.

Peripheral Artery Disease

Peripheral artery disease affects over 200 million people worldwide, yet current diagnostic tools do not provide detailed information about microvascular function and tissue oxygenation. Photoacoustic imaging of the lower extremities can measure hemoglobin oxygen saturation in skeletal muscle at rest and during exercise, providing a direct assessment of ischemic burden. A recent pilot study in patients with peripheral artery disease used a handheld photoacoustic probe to image the calf muscle before and after treadmill exercise. Results showed a significant reduction in tissue oxygen saturation in affected limbs compared with healthy controls, with recovery times prolonged in patients with more advanced disease. This functional information complements the anatomical data provided by ankle-brachial index measurements and could guide revascularization decisions.

Diabetic Foot Ulcers and Wound Healing

Diabetic foot ulcers are a serious complication of diabetes, often leading to amputation. Assessment of wound perfusion and oxygenation is critical for predicting healing outcomes and guiding treatment. Photoacoustic imaging has been applied to measure periwound oxygen saturation in diabetic patients with foot ulcers. In a prospective study involving 40 patients, photoacoustic imaging identified regions of tissue hypoxia that were not apparent on clinical examination or standard perfusion imaging. Wounds with uniformly high oxygen saturation in the surrounding tissue showed a significantly higher healing rate at 12 weeks compared with those with heterogeneous or low oxygenation. These findings suggest that photoacoustic imaging could become a routine tool in diabetic foot care clinics for objective wound assessment.

Deep Vein Thrombosis

Deep vein thrombosis affects an estimated 1 to 2 persons per 1000 annually and can lead to pulmonary embolism if untreated. Compression ultrasound is the current gold standard for diagnosis, but it has limited sensitivity for nonocclusive thrombi and provides no information about thrombus composition or age. Photoacoustic imaging of venous thrombi has been shown in animal models to distinguish acute fibrin-rich thrombi from chronic erythrocyte-rich thrombi based on their absorption spectra. This capability could aid in determining the optimal therapeutic approach, as acute thrombi respond better to thrombolysis while chronic thrombi may require mechanical intervention. Clinical translation of this application awaits the development of dedicated photoacoustic imaging systems for peripheral vascular imaging.

Integration with Other Imaging Modalities

Photoacoustic imaging is most powerful when used in conjunction with complementary imaging techniques. Combined photoacoustic and ultrasonic imaging systems are now commercially available for preclinical and early clinical research. In these systems, the same ultrasound detector array captures both photoacoustic signals from pulsed laser illumination and conventional pulse-echo ultrasound images from the same acoustic window. This dual-modality approach provides coregistered anatomical ultrasound images and functional photoacoustic maps of hemoglobin concentration, oxygen saturation, and contrast agent distribution. The registration is automatic and simultaneous, eliminating the need for post-acquisition image fusion.

Integration with computed tomography or magnetic resonance imaging is being explored for whole-body vascular assessment. Photoacoustic imaging can provide high-resolution functional data within a region of interest, while computed tomography or magnetic resonance imaging provides complete anatomical coverage and deep tissue penetration. Hybrid approaches such as magnetic resonance-guided photoacoustic imaging have been demonstrated in phantoms and small animals, using non-ferromagnetic transducers and fiber-optic light delivery to allow operation within an MRI scanner. This configuration is particularly attractive for applications requiring precise functional-anatomical correlation, such as stroke imaging or tumor vascular characterization.

Single-photon emission computed tomography and positron emission tomography continue to offer unique advantages for molecular imaging with extremely high sensitivity. Photoacoustic imaging cannot compete with nuclear medicine techniques in terms of tracer detection limits, but it offers superior spatial resolution and the ability to image at multiple time points without cumulative radiation exposure. Combining photoacoustic imaging with a positron emission tomography system for simultaneous acquisition is conceptually possible through careful design of the detector geometry and materials to avoid interference, though no commercial system currently exists.

Current Limitations and Ongoing Research Priorities

Despite significant progress, several barriers must be overcome before photoacoustic imaging becomes a standard clinical tool for vascular disease management. The most fundamental limitation is depth penetration. While optical clearing techniques and longer wavelength lasers (beyond 1000 nanometers) can extend imaging depth, penetration remains limited to approximately 5 to 7 centimeters in most tissues. This is adequate for peripheral vascular imaging and some deep structures with favorable optical properties, but insufficient for imaging central vasculature such as the aorta or coronary arteries from a transcutaneous approach.

Quantitative accuracy of chromophore concentration measurements is another area requiring improvement. The relationship between photoacoustic signal amplitude and chromophore concentration is influenced by wavelength-dependent light fluence distributions, which vary with depth and tissue type. Current fluence correction methods, including model-based inversion and deep learning approaches, improve accuracy but introduce computational complexity and assumptions about tissue optical properties. Standardization of calibration protocols and the development of robust, real-time fluence estimation algorithms remain active research areas.

Motion artifacts pose a particular challenge for cardiovascular photoacoustic imaging. Cardiac and respiratory motion can introduce misregistration between images acquired at different wavelengths, degrading spectral unmixing accuracy. Gated acquisition strategies using electrocardiogram or respiratory monitoring can mitigate motion effects but reduce temporal resolution. Real-time photoacoustic imaging systems with fast interleaved wavelength switching are being developed to acquire essentially simultaneous multispectral data, effectively freezing motion.

Regulatory approval and reimbursement pathways for photoacoustic imaging systems are still in early stages. The United States Food and Drug Administration has cleared a limited number of photoacoustic imaging devices for clinical research use, but none yet for specific vascular disease indications as a primary diagnostic tool. Building the clinical evidence base through well-designed multicenter trials with adequate statistical power and standardized imaging protocols is a priority for the field.

Future Outlook and Clinical Translation Timeline

The trajectory of photoacoustic imaging technology suggests that clinical translation will accelerate over the next five to ten years. Several factors support this outlook. First, the development of compact, cost-effective laser sources based on solid-state technologies and fiber lasers has reduced system size and cost, making clinical deployment more practical. Second, the convergence of photoacoustic imaging with established ultrasound platforms means that the incremental cost of adding photoacoustic capability to existing ultrasound systems is relatively modest, particularly as laser costs continue to decline.

Portable and handheld photoacoustic imaging devices are already entering clinical research settings. These systems, weighing less than 10 kilograms and integrated with commercial ultrasound probes, allow imaging at the bedside, in outpatient clinics, or in operating rooms. The potential for point-of-care assessment of tissue oxygenation in critical care, trauma, and chronic wound management is driving commercial investment and clinical interest.

Artificial intelligence and machine learning will play an increasingly important role in photoacoustic image reconstruction, spectral unmixing, and clinical decision support. Deep learning approaches trained on large datasets of paired photoacoustic images and ground truth measurements have already shown the ability to reduce reconstruction artifacts and improve quantitative accuracy. Machine learning classification of photoacoustic spectra for tissue characterization, such as distinguishing lipid-rich from fibrous plaques, is being explored as a diagnostic aid for vascular disease assessment.

The next decade will likely see photoacoustic imaging becoming a complementary modality within a multimodality vascular imaging armamentarium, rather than replacing existing techniques outright. Its unique strength lies in providing functional information about blood oxygenation and microvascular perfusion that is currently unavailable with conventional imaging methods. As the technology matures and clinical evidence accumulates, photoacoustic imaging is positioned to improve diagnostic accuracy, guide treatment decisions, and enable earlier intervention in patients with vascular disease. Ongoing collaboration between engineers, physicists, clinicians, and industry partners is essential to translate these advances into routine clinical practice and, ultimately, to improve patient outcomes across the spectrum of vascular pathology.